Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to cyclopentano-hydrophenanthrene ; derivative thereof
Reexamination Certificate
1999-11-01
2001-06-26
Jones, Dameron L. (Department: 1619)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to cyclopentano-hydrophenanthrene ; derivative thereof
C564S305000, C568S579000, C568S924000, C424S001110, C424S009100, C424S001650
Reexamination Certificate
active
06251363
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a diagnostic and therapeutic 1-[2-(diarylmethxoy) ethyl]-4-(3-aryalkyl) alpha, omega alkylenediamines, their use as diagnostic or therapeutic agents and to a process for making the alkylenediamines.
2. Description of Prior Art
The dopaminergic (DA) neurotransmitter systems are intimately involved with a number of nervous system (CNS) disorders including those involved with movement, e.g., Parkinson's Disease and reinforcing effects, e.g., cocaine dependency. Interest in these two disorders in particular has stimulated research efforts to develop specific agents that can be used either diagnostically, to evaluate the extent of the disease, or therapeutically to antagonize the effect of cocaine. Cocaine recognition sites are localized on dopamine nerve terminals. Drugs that bind, affect or block these sites therefore have potential uses which include: (i) imaging probes for neurodegenerative disorders; and (ii) imaging probes for dopamine transporter/cocaine binding sites. Furthermore, in many instances these compounds or analogs become active on other sites that affect the serotonergic system and, therefore, may be used to treat disorders associated with serotonin (e.g., depression, PMS, weight, or aging).
Because of the unique anatomical location of the cocaine recognition sites, a high affinity probe for imaging of these sites in vivo in the brain can be carried out using positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging. Such imaging is useful for diagnosing or monitoring the Parkinson's disease, other neurological disorders characterized by the degeneration of dopamine nerve terminals or by aging. Preferably, the common target for compounds that would fulfill these objectives is the dopamine transporter (DAT), a 12-transmembrane spanning presynaptic protein that removes the dopamine from the synaptic cleft following it release. The two classes of competitive drugs that have been most extensively examined are the stable tropane analogs of cocaine characterized by WIN 35,428 (also known as CFT) and the piperazine derivatives characterized by GBR-12935. Both exert their effect at nanomolar concentrations.
The cocaine analog, 2&bgr;-carbomethoxy-3&bgr;-(4-fluorophenyl) tropane (CFT) and other analogs have proven to be an effective probe for studying dopamine-related diseases and cocaine binding sites in the striatum. For example, the progression of Parkinson's disease in prime models and subjects can be monitored by administering radiolabeled analogs of CFT and imaging the distribution of radioactivity in the brain PET has been used to image
11
C labeled analogs of CFT in primate models, Hantraye et al., Neuroreport 3.265 (1992), Farde et al., Synapse 16:93 (1994) while SPECT has been used to image iodinated CFT analogs in both primate models and human subjects (Shaya et al., Synapse 10:169 (1992) and Neumeyer et al., J. Med. Chem 34:3144 (1991, Elmaleh et al. J. Nucl. Med.
Various substances (particularly cocaine and cocaine congeners) are potent inhibitors of dopamine transport in the striatum of the brain because they bind to the dopamine transporter. These substances have different affinities or Ic
50
's for inhibiting dopamine transport and for blocking cocaine. The more strongly these substances block dopamine transport, the more strongly they bind to sites on the dopamine transporter which have been labeled by [
3
M] cocaine or by [
3
H] CFT, Madras et al., (1089)
J. Pharmacol. Exp. Ther.
251:131-141; and Madras et al. (1989)
Mol. Pharmacol.
36:518-524. The hope that these compounds might be Parkinson's markers is further supported by the parallel between loss of binding and loss of dopamine in the diseased brain (Madras et al.
Catechol. Symp.
193, 1992).
Because of its widespread, low cost and simplicity, SPECT is preferred to PET for routine imaging directed towards diagnosis. Technetium-99m is the tracer of choice for SPECT imaging because of its excellent physical characteristics and widespread availability. Recently, technetium-99m CFT analogs were reported which appear to be extracted by the brain and concentrate preferentially in its dopamine rich regions (Madras et al., Synapse 22:239 (1996) and Meegalla et al., J. Am Chem. Soc. 117:11037 (1995).
There is need for improved diagnostic agents and markers of neurogenerative disorders which have improved specificity for concentrating in dopamine rich regions in the brain Such agents can provide improved diagnosis for excluding at an early stage of Parkinson's disease as the cause of symptoms which may be useful information in diagnosing other conditions. Moreover, early diagnosis of Parkinson's disease can facilitate the introduction of putative prophylactic drug therapy (e.g., deprenyl) prior to the onset of more severe symptoms, Kaufman and Madras (1991) Synapse 9:43-49. Detection of nerve cell depletion in the presymptomatic phase in an animal model of Parkinson's disease would also be useful, e.g., when using the model to evaluate therapies for Parkinson's disease, Hantraye et al. (1992) Neurol. Reports 3:26-268; and Hahtraye et al. (1992)
Soc. Neurosci. Abstra.
18:935.
There is a particular need for diagnostic agents and markers of neurogenerative disorders that selectively target a domain transporting protein (the dopamine transporter) in preference to another protein known as the serotonin transporter. In normal brain tissue, the dopamine: serotonin transporter density ratio is approximately 10:1. Diagnostic agents can be used to monitor the effects of Parkinson's disease therapy by determining the loss or reduction of loss of dopamine. In certain neurodegenerative disorders, such as Parkinson's disease, nerve cells that produce dopamine (and on which the dopamine transporter is located) undergo severe depletion while serotonin transporter ratio can fall to 50% in Parkinson's disease.
Accordingly, it would be desirable to provide improved diagnostic and therapeutic compositions which have improved selectivity for being concentrated in dopamine regions of the brain as compared to presently available diagnostic and therapeutic compositions. Such improved diagnostic and therapeutic compositions can provide a means for earlier detecting an abnormal condition of the brain measurable by determining the state of the dopamine rich regions. In addition, such improved therapeutic composition can provide a basis for more effective treatment of a patient such as a cocaine-dependent patient.
SUMMARY OF THE INVENTION
The present invention is based on the discovery that N-[2-bis-[arylmethoxy) ethyl-N
1
-arylalkyl -&agr;, &ohgr;-alkanediamines have high affinity and high selectivity for dopamine transporters.
The compounds of this invention are represented by the Formula I and physiologically acceptable salts thereof:
wherein:
l, m and n can be the same or different and are an integer of 1 to 6; X, Y and Z can be the same or different and are hydrogen, halo, haloalkyl, (C
1
-C
6
) alkyl, aryl, (C
1
-C
6
) alkoxy, N-alkyl, (C
2
-C
6
) acyloxy, N-alkylene, —SH, or —SR, wherein R is from the same group as R
1
and R
2
and can be the same or different than R
1
and R
2
, amino, nitro, cyano, hydroxy, —C(═O) OR
6
, —C(═O) NR
5
R
4
, —NR
3
R
2
, or —S(═O)
k
R
1
wherein
k
is 1 or 2, and R
3
to R
6
are independently hydrogen or (C
1
-C
6
) alkyl;
R
1
, and R
2
can be the same or different and are hydrogen, (C
1
-C
6
) alkyl, hydroxyalkyl or mercaptoalkyl, —C(═O) OR
1
, cyano, (C
1
-C
6
) alkenyl, (C
2
-C
6
) alkynyl, or 1,2, 4-oxadiazol-5-yl optionally substituted at he 3-position by W wherein any (C
1
-C
6
) alkyl, (C
1
-C
6
) alkanoyl, (C
2
-C
6
) alkenyl or (C
2
-C
6
) alkynyl can optionally be substituted by 1, 2 or 3 Z;
W is (C
1
-C
6
) alkyl or phenyl, optionally substituted by 1, 2 or 3 Z.
&PHgr; is phenyl, naphthyl, thienyl or pyridinyl.
The compounds of this inven
Elmaleh David R.
Hanson Robert N.
Sung-Woon Choi
Cook Paul J.
Jones Dameron L.
The General Hospital
LandOfFree
Diagnostic and therapeutic alkylenediamine compounds and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic and therapeutic alkylenediamine compounds and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic and therapeutic alkylenediamine compounds and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2461953